Australian COPD Drugs Market 2023 | Estimate CAGR Analysis, Technological Development Overview, Growth Trends and Competitive Research till 2028

Report Overview

The Australian COPD Drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

In 2014 COPD was the fifth leading cause of death in Australia. In that year 7,025 people died from COPD (4.6% of all deaths). One of the best ways Australians can prevent COPD is to avoid smoking or stop smoking if already a smoker. Several new COPD inhalers have been released into the Australian market in recent years to help people manage their condition. The new NPS MedicineWise educational program will help consumers and health professionals select inhaler medicines that best match individual needs, and this drive the growth of the Australian COPD market in the forecasted period.

Market Drivers

Certain factors that are driving the market growth include an increase in incidence and prevalence of COPD, an increased number of smokers, and a growing geriatric population.

The Australian population is aging, with older Australians a growing proportion of the total population. In 2017, 15% of Australians (3.8 million) were aged 65 and over; this proportion is projected to grow steadily over the coming decades. Over 1 in 7 Australians are aged 65 and over, around half of the older Australians aged 665 and aver are women, & 3 in 10 older Australians aged 65 and over were born overseas.

In Australia, the main cause of COPD is smoking however COPD can occur in people who have never smoked a cigarette in their lives. Exposure to passive smoke, outdoor air pollution, occupational chemicals, and dust are other known risk factors. Men and women smoked a similar number of cigarettes per day in 2019an average of 13.1 and 12.9 cigarettes per day respectively in Australia.

Epidemiology

The development of COPD occurs over many years and therefore affects mainly middle-aged and older people. The prevalence of COPD increases with age, mostly occurring in people aged 45 and over.

In the 201718 ABS National Health Survey (NHS), the prevalence of COPD (captured here as self-reported emphysema and/or bronchitis) in Australians aged 45 and over was 4.8%, or an estimated 464,000 people (ABS 2018). Overall, the prevalence did not differ significantly between men and women (4.5% and 5.1% respectively) however, for those aged 5564, COPD was more prevalent in women compared with men (6.2% and 3.6%, respectively).

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/140026/

Major Players

The industry is competitive in nature with key players involved in mergers & acquisitions, new product development, collaborations & partnerships, and expansion strategies to augment market penetration. The key players in the COPD market are AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Abbott Laboratories, & Teva Pharmaceutical.

The Australian COPD Drugs Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Australian COPD Drugs market. This report explores all the key factors affecting the growth of the global Australian COPD Drugs market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On Australian COPD Drugs Market @ https://www.prudentmarkets.com/sample-request/140026/

Market Segmentation

By Type:

COPD (which includes chronic bronchitis and emphysema) is a common disease in Australia and a major cause of disability, hospital admissions, and mortality. It is ranked third in the overall burden of disease after heart disease and stroke. More than half a million Australians are estimated to suffer from moderate to severe disease, and COPD ranks fourth among the common causes of death in Australian men, and sixth in women. Rates are even significantly higher in the Australian Aboriginal population.

Chronic bronchitis is common among smokers. In Western countries, it is estimated that chronic bronchitis occurs in approximately 18% of male and 14% of female smokers compared to 7% and 6% of non-smokers, respectively.

By Drug Class:

Based on the Drug Class the market is segmented into Short-acting bronchodilators: help open your airways to make breathing easier, Corticosteroids: reduces inflammation in the body, making airflow easier in the lungs, Methylxanthines: anti-inflammatory drug and relaxes the muscles in the airways, Long-acting bronchodilators:  help ease breathing, they don't act as quickly as rescue medication, Combination drugs: recommended for those who continue to have shortness of breath or trouble breathing and are currently using LABA and LAMA combination therapy, Roflumilast: helps relieve inflammation, which can improve airflow to your lungs, Mucoactive drugs: help reduce mucus or thin it so you can more easily cough it up, Vaccines: reduce your risk for getting sick and can help you avoid infections and other complications related to COPD, & Others.

Major Players

The industry is competitive in nature with key players involved in mergers & acquisitions, new product development, collaborations & partnerships, and expansion strategies to augment market penetration. The key players in the COPD market are AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Abbott Laboratories, & Teva Pharmaceutical.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/140026/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global Australian COPD Drugs Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global Australian COPD Drugs Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Australian COPD Drugs market
Chapter 2: Exclusive Summary - the basic information of the Australian COPD Drugs Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Australian COPD Drugs
Chapter 4: Presenting the Australian COPD Drugs Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Australian COPD Drugs market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/140026/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the Australian COPD Drugs Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.